🚀 VC round data is live in beta, check it out!
Rigel Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Rigel Pharmaceuticals and similar public comparables like Kyverna Therapeutics, TTY Biopharm, Prothena Corp., Luzhu Biotech and more.
Rigel Pharmaceuticals Overview
About Rigel Pharmaceuticals
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Founded
1996
HQ
Employees
164
Website
Financials (LTM)
EV
$498M
Rigel Pharmaceuticals Financials
Rigel Pharmaceuticals reported last 12-month revenue of $291M and EBITDA of $120M.
In the same LTM period, Rigel Pharmaceuticals generated $271M in gross profit, $120M in EBITDA, and $283M in net income.
Revenue (LTM)
Rigel Pharmaceuticals P&L
In the most recent fiscal year, Rigel Pharmaceuticals reported revenue of $294M and EBITDA of $132M.
Rigel Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $291M | XXX | $294M | XXX | XXX | XXX |
| Gross Profit | $271M | XXX | $275M | XXX | XXX | XXX |
| Gross Margin | 93% | XXX | 93% | XXX | XXX | XXX |
| EBITDA | $120M | XXX | $132M | XXX | XXX | XXX |
| EBITDA Margin | 41% | XXX | 45% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 43% | XXX | XXX | XXX |
| Net Profit | $283M | XXX | $367M | XXX | XXX | XXX |
| Net Margin | 97% | XXX | 125% | XXX | XXX | XXX |
| Net Debt | — | — | $12M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Rigel Pharmaceuticals Stock Performance
Rigel Pharmaceuticals has current market cap of $599M, and enterprise value of $498M.
Market Cap Evolution
Rigel Pharmaceuticals' stock price is $32.43.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $498M | $599M | 0.0% | XXX | XXX | XXX | $19.86 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRigel Pharmaceuticals Valuation Multiples
Rigel Pharmaceuticals trades at 1.7x EV/Revenue multiple, and 4.2x EV/EBITDA.
EV / Revenue (LTM)
Rigel Pharmaceuticals Financial Valuation Multiples
As of April 20, 2026, Rigel Pharmaceuticals has market cap of $599M and EV of $498M.
Equity research analysts estimate Rigel Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Rigel Pharmaceuticals has a P/E ratio of 2.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $599M | XXX | $599M | XXX | XXX | XXX |
| EV (current) | $498M | XXX | $498M | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 4.2x | XXX | 3.8x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 4.0x | XXX | XXX | XXX |
| EV/Gross Profit | 1.8x | XXX | 1.8x | XXX | XXX | XXX |
| P/E | 2.1x | XXX | 1.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 6.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Rigel Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Rigel Pharmaceuticals Margins & Growth Rates
Rigel Pharmaceuticals' revenue in the last 12 month grew by 1%.
Rigel Pharmaceuticals' revenue per employee in the last FY averaged $1.8M, while opex per employee averaged $0.9M for the same period.
Rigel Pharmaceuticals' rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Rigel Pharmaceuticals' rule of X is 28% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Rigel Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | (3%) | XXX | XXX | XXX |
| EBITDA Margin | 41% | XXX | 45% | XXX | XXX | XXX |
| EBITDA Growth | (5%) | XXX | (21%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 33% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 28% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.8M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 40% | XXX | 39% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Rigel Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Rigel Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Kyverna Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| TTY Biopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Prothena Corp. | XXX | XXX | XXX | XXX | XXX | XXX |
| Luzhu Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Cormedix | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Rigel Pharmaceuticals M&A Activity
Rigel Pharmaceuticals acquired XXX companies to date.
Last acquisition by Rigel Pharmaceuticals was on XXXXXXXX, XXXXX. Rigel Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Rigel Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRigel Pharmaceuticals Investment Activity
Rigel Pharmaceuticals invested in XXX companies to date.
Rigel Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Rigel Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Rigel Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Rigel Pharmaceuticals
| When was Rigel Pharmaceuticals founded? | Rigel Pharmaceuticals was founded in 1996. |
| Where is Rigel Pharmaceuticals headquartered? | Rigel Pharmaceuticals is headquartered in United States. |
| How many employees does Rigel Pharmaceuticals have? | As of today, Rigel Pharmaceuticals has over 164 employees. |
| Who is the CEO of Rigel Pharmaceuticals? | Rigel Pharmaceuticals' CEO is Raul R. Rodriguez. |
| Is Rigel Pharmaceuticals publicly listed? | Yes, Rigel Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Rigel Pharmaceuticals? | Rigel Pharmaceuticals trades under RIGL ticker. |
| When did Rigel Pharmaceuticals go public? | Rigel Pharmaceuticals went public in 2000. |
| Who are competitors of Rigel Pharmaceuticals? | Rigel Pharmaceuticals main competitors are Kyverna Therapeutics, TTY Biopharm, Prothena Corp., Luzhu Biotech. |
| What is the current market cap of Rigel Pharmaceuticals? | Rigel Pharmaceuticals' current market cap is $599M. |
| What is the current revenue of Rigel Pharmaceuticals? | Rigel Pharmaceuticals' last 12 months revenue is $291M. |
| What is the current revenue growth of Rigel Pharmaceuticals? | Rigel Pharmaceuticals revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Rigel Pharmaceuticals? | Current revenue multiple of Rigel Pharmaceuticals is 1.7x. |
| Is Rigel Pharmaceuticals profitable? | Yes, Rigel Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Rigel Pharmaceuticals? | Rigel Pharmaceuticals' last 12 months EBITDA is $120M. |
| What is Rigel Pharmaceuticals' EBITDA margin? | Rigel Pharmaceuticals' last 12 months EBITDA margin is 41%. |
| What is the current EV/EBITDA multiple of Rigel Pharmaceuticals? | Current EBITDA multiple of Rigel Pharmaceuticals is 4.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.